Cushing syndrome associated with an adrenal tumour

Vieira, Helena; Brain, Caroline

doi:10.1136/bcr-2012-006685

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypersensitivity to metyrapone or any of the excipientsHow should metyrapone be used in special populations?Paediatric patientsNo specific dosage adjustment required (limited data; 21 case reports[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23], including 1 case of rectal administration[21]); adjust based on cortisol levels and tolerabilityElderly patients (≥ 65 years) No specific dosage adjustment required (limited data) [11 case reports[16,[24][25][26]]What other special warnings and precautions pertain to the use of metyrapone?Excipients b Delayed allergic reactions may occurAssay methods Measure plasma/serum and urine cortisol levels using a reliable assay without cross-reactivity with steroids precursors (e.g. a specific immuno-assay or a liquid chromatography-mass spectrometry method) to allow accurate dose adjustment Supervision Monitor and instruct patients on the signs and symptoms of hypocortisolism; manage hypocortisolism with temporary exogenous steroid replacement therapy and/or dose modification (reduction or interruption), as necessary…”

mentioning

confidence: 99%

Metyrapone in Cushing’s syndrome: a profile of its use

Al-Salama

2021

Drugs Ther Perspect

View full text Add to dashboard Cite

Metyrapone (Metopirone ® ), a pyridine derivative, is a useful treatment option for the management of patients with endogenous Cushing's syndrome, based on evidence from more than six decades of its use in clinical practice, prospective and retrospective studies, as well as case reports. Metyrapone is associated with a rapid onset of action and is effective in reducing cortisol levels and improving clinical and/or biochemical features and cortisol-related comorbidities of Cushing's syndrome. The efficacy of metyrapone was demonstrated in all aetiologies of the condition, when used in a range of clinical settings (including presurgery treatment and when used in combination with other drugs) and in the short and long term. Metyrapone is generally well tolerated when used in the treatment of patients with endogenous Cushing's syndrome, with gastrointestinal adverse events being the most commonly reported. Plain Language SummaryEndogenous Cushing's syndrome is a rare disease, resulting from cortisol hypersecretion, and is associated with substantial morbidity and mortality. Surgery is the mainstay treatment for the majority of patients with Cushing's syndrome; however, medical therapy is increasingly being used, particularly when surgery is not indicated or is unsuccessful, or while waiting for radiotherapy to be effective. Oral metyrapone (Metopirone ® ), a pyridine derivative, is approved for the management of endogenous Cushing's syndrome in the EU. Evidence for the efficacy of metyrapone in the treatment of Cushing's syndrome has been demonstrated in prospective and retrospective studies. Metyrapone has a rapid onset of action (≈ 2 h), reduces cortisol levels, improves the clinical and/or biochemical features and cortisol-related comorbidities of the disease, and demonstrates sustained efficacy in the long term; the efficacy of metyrapone is evident in a range of clinical settings. Metyrapone is generally well tolerated in patients with endogenous Cushing's syndrome. Given its efficacy and tolerability profile, metyrapone is a useful treatment option for the management of patients with endogenous Cushing's syndrome.

show abstract

mentioning

confidence: 99%

Metyrapone in Cushing’s syndrome: a profile of its use

Al-Salama

2021

Drugs Ther Perspect

View full text Add to dashboard Cite

show abstract

“…The rarity of ACTs in children can cause difficulties with diagnosis. Most of the available scientific papers describe individual cases observed for only a few years (Table 2) [8,[13][14][15].…”

Section: Discussionmentioning

confidence: 99%

Cushing’s syndrome as a rare manifestation of adrenal tumours in infants – case report

Badurowicz¹,

Stefanowicz²,

Jezierska³

et al. 2019

polp

View full text Add to dashboard Cite

We report a case of a six-week-old male infant with a congenital tumour of the left suprarenal gland. The tumour was diagnosed by ultrasound examination (USG) as a neonatal suprarenal mass. By the third month of life, the patient had typical signs of Cushing's syndrome. Based on the results of hormonal tests and imaging studies (USG and MRI), an adrenocortical tumour was suspected. The patient could only be cured by surgery. Histopathological examination confirmed clinical diagnosis of an adrenocortical tumour. We concluded that Cushing's syndrome may be a rare clinical manifestation of adrenal tumour in neonates. Only careful observation allows for proper diagnosis and appropriate treatment. Correct diagnosis is essential for optimal postnatal treatment.

show abstract

“…The majority of cases present with a combination of clinical features of Cushing's syndrome and hyperandrogenism with or without pulmonary metastasis. [1][2][3] Hypertension may not be always present. 4 Diagnosis depends on clinical manifestations, demonstration of elevated hormone levels and localization of tumour(s).…”

Section: Introductionmentioning

confidence: 99%

A Rare Case of Adrenocortical Carcinoma

2013

View full text Add to dashboard Cite

A 15 year old girl was admitted with absence of menstruation and increase growth of facial and body hair for two years along with change of voice for six months. With these complaint, tablet progesterone was advised but there was no withdrawal bleeding. On examination she had hirsuitism. She had normal female secondary sex characteristics with mild clitoromegaly. Her investigations revealed hyperandrogenemia with normal level of other adrenal hormones. Imaging revealed left adrenal mass. Left adrenalectomy done and histopathology revealed malignant tumor of Zona reticularis. Adrenocortical carcinoma is a rare tumor and only limited information is available about its natural history and the effects of therapy. The case is a rare androgen producing malignant tumor of adrenal having an earlier age of presentation. Birdem Med J 2013; 3(2): 110-112 DOI: http://dx.doi.org/10.3329/birdem.v3i2.17216

show abstract

Cushing syndrome associated with an adrenal tumour

Cited by 5 publications

References 6 publications

Metyrapone in Cushing’s syndrome: a profile of its use

Metyrapone in Cushing’s syndrome: a profile of its use

Cushing’s syndrome as a rare manifestation of adrenal tumours in infants – case report

A Rare Case of Adrenocortical Carcinoma

Contact Info

Product

Resources

About